CD19 and acute lymphoblastic leukemia: According to the latest data from ClinicalTrials.gov, 54 clinical trials of CAR-NK are underway, with approximately 33.3% focused on CD19 CAR-NK, highlighting the significant potential of CAR-NK cell therapy in overcoming ALL.